Adapsyn Bioscience Inc., a biotechnology company focused on the discovery and development of novel medicines derived from evolved small molecule natural products, today announced that it has completed a round of financing that was co-funded by Pfizer R&D Innovate and Genesys Capital. In addition, the company has announced a research collaboration with Pfizer Inc.
Natural products are organic biomolecules produced by nature and, particularly those produced by microbiota, represent a rich source of evolutionarily optimized biologically active molecules. The Adapsyn platform combines genomic and metabolomic data with artificial intelligence and machine-learning to identify novel, mechanistically diverse evolved small molecules from human and environmental microbiomes. The financing will support the company’s internal drug development programs.
“We are excited to apply our platform to unlock the unique targeting capacity of these evolved compounds and realize new therapeutics,” commented Nathan Magarvey, PhD, Founder and Chief Scientific Officer of Adapsyn. “Recent technological advances in machine learning, artificial intelligence, and large-scale genomic and metabolomic analysis are reenergizing the field of natural product drug development, and Adapsyn is excited to be at the forefront of this work.”
Under the terms of the research agreement, Adapsyn and Pfizer are working together to employ Adapsyn’s proprietary platform technologies with the goal of identifying and testing previously undiscovered natural products from Pfizer’s collection of microbial strains. Both companies have exclusive rights to pursue select novel compounds and their derivatives identified through the collaboration. In addition to an upfront payment, should Pfizer advance any potential compounds identified through the collaboration, Adapsyn is entitled to potential preclinical, and regulatory milestone payments of up to $162 million, as well as royalties on potential future sales of any product that may be derived from this collaboration. Should Adapsyn advance any potential compounds identified through the collaboration, Pfizer will be eligible for future milestone and royalty payments as well.
To read the full article, click here